GICS Sector : Healthcare
Omega Therapeutics, Inc.operates as a development-stage biopharmaceutical company.Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Omega Pacific Acquires 100% of Williams Property
Nov -24
Omega Pacific Closes Non-Brokered Private Placement
Oct -15
Omega Pacific Closes First Tranche of Offering
Aug -18
Omega Pacific Announces Private Placement
Jun -17
Omega Pacific Outlines 2025 Exploration Program in the Revitalized Toodoggone District
Jun -04
Omega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams Property
Dec -04
Omega Pacific Announces 2024 Work Program Results From Its Lekcin Property
Nov -19
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates
Nov -14
Omega Therapeutics' Programmable Epigenomic mRNA Medicines growth is driven by increasing adoption in oncology and rare genetic disorders, strong pipeline of novel therapies, strategic partnerships, and growing demand for precision medicine. Additionally, advancements in mRNA technology and epigenomic editing enable targeted and efficient treatment approaches, further fueling growth.
A gene editing platform that enables precise and efficient editing of genes for the treatment of genetic diseases
A platform that enables the precise control of gene expression for the treatment of complex diseases
A platform that enables the precise editing of genes in vivo for the treatment of genetic diseases
A platform that enables the precise editing of genes in the brain for the treatment of neurological disorders
Omega Therapeutics, Inc. faces moderate threat from substitutes due to the availability of alternative treatments and therapies.
Omega Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers.
Omega Therapeutics, Inc. relies on a few key suppliers for raw materials, which gives them some bargaining power.
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services.
The biotechnology industry is highly competitive, and Omega Therapeutics, Inc. faces intense rivalry from established players and new entrants.
| Value | |
|---|---|
| Debt Weight | 34.22% |
| Debt Cost | 3.95% |
| Equity Weight | 65.78% |
| Equity Cost | 13.86% |
| WACC | 10.47% |
| Leverage | 52.03% |
Value: 7.0
Growth: 2.4
Quality: 3.1
Yield: 0.0
Momentum: 5.0
Volatility: 1.0
1-Year Total Return ->
Value: 7.6
Growth: 4.1
Quality: 3.2
Yield: 0.0
Momentum: 2.0
Volatility: 0.7
1-Year Total Return ->
Value: 8.0
Growth: 4.1
Quality: 4.9
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->
Value: 7.6
Growth: 4.8
Quality: 3.3
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->
Value: 7.8
Growth: 4.8
Quality: 2.4
Yield: 0.0
Momentum: 0.5
Volatility: 0.0
1-Year Total Return ->
Value: 8.8
Growth: 3.4
Quality: 2.5
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->